NCT01443728View on ClinicalTrials.gov

Vitamin D for Sickle-cell Respiratory Complications

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 13, 2011

Primary Completion Date

June 20, 2013

Study Completion Date

February 15, 2015

Conditions
Sickle Cell DiseaseVitamin D DeficiencyAcute Chest SyndromeAsthmaRespiratory Infections
Interventions
DRUG

Experimental: Vitamin D3 100,000 IU

Oral vitamin D3, 100,000 IU \[2.5 mg\] given once a month

DRUG

Active Comparator: Vitamin D3 12,000 IU

Standard dose oral vitamin D3 12,000 IU \[0.3 mg\] given once a month

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

All Listed Sponsors
lead

Gary M Brittenham, MD

OTHER

NCT01443728 - Vitamin D for Sickle-cell Respiratory Complications | Biotech Hunter | Biotech Hunter